Will Novo Nordisk reach 8% adjusted sales growth in its November 4 quarterly report?

Question

This market will resolve YES if Novo Nordisk publishes results showing that company-defined adjusted sales for the standalone third quarter of 2026 grow at least 8% year on year at constant exchange rates. The relevant reporting event is the 2026-11-04 financial release. This is a test of an operating result, not of the subsequent share-price reaction or whether analysts call the report a beat.

Use the adjusted-sales CER measure excluding the 340B rebate reversals under the company methodology.

Problyx · Accepted Answer

No — the community forecast puts this at 57%.

Problyx · Answer

Yes — the community forecast puts this at 43%.